Menu

Pfizer

Phase 3 Prosper Trial Shows Xtandi® (Enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-metastatic Castration-resistant Prostate Cancer

, , , ,

TOKYO and NEW YORK, February 5, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Pfizer Inc. (NYSE: PFE) announced today results from the Phase 3 PROSPER trial in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC). The results show that the use of XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) […]

Kite Announces Clinical Collaboration to Evaluate Investigational Combination of Yescarta™ (Axicabtagene Ciloleucel) and Pfizer’s Utomilumab in Large B-Cell Lymphoma

, , , , ,

Phase 1/2 Study Planned for 2018 FOSTER CITY, Calif. & SANTA MONICA, Calif.–(BUSINESS WIRE)–Jan. 18, 2018– Kite, a Gilead Company (Nasdaq: GILD), announced it has entered into a clinical trial collaboration with Pfizer, Inc. to evaluate the safety and efficacy of the investigational combination of Yescarta™ (axicabtagene ciloleucel) and Pfizer’s utomilumab, a fully humanized 4-1BB agonist monoclonal antibody, in patients with […]

Pfizer Receives U.S. FDA Approval for Besponsa® (Inotuzumab Ozogamicin)

, , , ,

BESPONSA is the first and only CD22-directed antibody-drug conjugate indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia NEW YORK – August 17, 2017 – Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BESPONSA® (inotuzumab ozogamicin) for the treatment of adults with relapsed […]

FDA Advisory Committee Votes in Favor of Xeljanz® (Tofacitinib Citrate) for the Treatment of Active Psoriatic Arthritis

, , ,

NEW YORK, August 3, 2017 – Pfizer Inc. announced today that the United States Food and Drug Administration’s (FDA) Arthritis Advisory Committee (AAC) voted 10 to 1 to recommend approval of the proposed dose of tofacitinib for the treatment of adult patients with active psoriatic arthritis (PsA). Pfizer submitted supplemental new drug applications (sNDAs) for […]

Pfizer Announces Positive Top-line Results From the Comparative Reflections B7391003 Study for PF-06439535, a Potential Biosimilar to Avastin®1 (Bevacizumab)

, , , ,

Results demonstrate equivalence in objective response rate in patients with advanced non-squamous non-small cell lung cancer NEW YORK, July 24, 2017 – Pfizer Inc. (NYSE:PFE) today announced that the REFLECTIONS B7391003 study, a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin® (bevacizumab), met its primary objective. PF-06439535 is being developed by Pfizer as […]

Non-Profit Organizations Invited to Apply for Grants to Improve Access to Diabetes Care

, , ,

November 17, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–The Merck Foundation (Foundation) announced today the launch of a new initiative, Bridging the Gap: Reducing Disparities in Diabetes Care (Bridging the Gap), to improve access to high-quality diabetes care and reduce health disparities for vulnerable and underserved populations in the United States. With $10 million in funding from the […]

Pfizer to Collaborate with National Cancer Institute to Study Three Immunotherapy Agents Targeting Multiple Cancers

, , , ,

Cooperative Research and Development Agreement (CRADA) assesses OX40 agonist, utomilumab and avelumab immuno-oncology assets alone and in various combinations November 14, 2016 – Pfizer Inc. (NYSE:PFE) today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). As part […]

Landmark Study Demonstrates Pfizer’s Celebrex (Celecoxib) Has Similar Cardiovascular Risk As Compared To Prescription Doses Of Ibuprofen and Naproxen

, , , ,

Patients Taking Pfizer’s Celebrex (celecoxib) Experienced Fewer Gastrointestinal Events As Compared to Prescription Doses of Ibuprofen and Naproxen Study Findings Dispel Long Standing Perceptions of Excess Cardiovascular Risk Associated With Long Term Use Of Celebrex Results of PRECISION Study Presented at the Annual Meeting of the American Heart Association in New Orleans Provide Important Information […]

Pfizer Announces Major Expansion of Humanitarian Assistance Program

, ,

Prevenar 13® Vaccine Will Be Available at Lowest Price for Humanitarian Emergencies Pfizer to Donate Sales Proceeds to Organizations Supporting the Refugee Crisis November 11, 2016 – Pfizer Inc. (NYSE:PFE) announced today a major expansion of its humanitarian assistance program enabling broader access to its vaccine, Prevenar 13, in humanitarian emergency settings by offering its […]

Spark Therapeutics and Pfizer Announce Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Sustained Therapeutic Levels of Factor IX Activity

, , ,

First seven participants, through a combined 103 weeks of observation as of Aug. 4, 2016, did not need infusions of factor IX concentrates to prevent bleeding Updated SPK-9001 data in hemophilia B to be presented at the Plenary Scientific Session at 58th American Society of Hematology Annual Meeting November 3, 2016 – PHILADELPHIA and NEW […]

1 2